Financial Performance and Growth Strategy - Incyte aims to transition into a high-growth Hematology-Oncology-IAI company[4] - The company targets a 15%-20% 5-year CAGR with a diversified franchise and minimal LOE exposure, targeting a $7-8 billion cash balance by 2030[14] - Incyte's core business (excluding Jakafi) is projected to grow to $3-4 billion by 2030[11, 14] - The core business (ex-Jakafi) experienced a 45% year-over-year revenue growth from 2024 to 2025[19, 23] Pipeline and Product Development - Incyte anticipates launching Jakafi XR, Opzelura (mAD), povorcitinib, and Monjuvi (1L DLBCL)[11] - The company has seven high-value pipeline assets with a potential peak net sales opportunity of over $10 billion[11, 25] - Fourteen pivotal trials across seven assets are expected by the end of the year[12] - Povorcitinib is projected to achieve over $1 billion in sales across three indications[56] Jakafi Performance - 2025 Jakafi net product revenue guidance is between $3050 million and $3075 million[18] - Jakafi volume increased 10% compared to the prior year[70, 71] Opzelura Performance - 2025 Opzelura net revenue guidance is between $630 million and $670 million[18]